Stoschitzky Kurt, Koshucharova Gergana, Zweiker Robert, Lercher Peter, Maier Robert, Klein Werner, Zitta Sabine, Gruber Leonhard, Lamprecht Günther, Lindner Wolfgang
Division of Cardiology, Karl Franzens University, Graz, Austria.
Cardiovasc Drugs Ther. 2002 Mar;16(2):133-40. doi: 10.1023/a:1015705516496.
In vitro studies have shown that beta-blockers are taken up into and released from adrenergic cells. As a consequence, plasma concentrations of beta-blockers increase during exercise together with those of epinephrine and norepinephrine. However, effects of exercise on plasma concentrations of (R)- and (S)-carvedilol are unknown.
Twelve healthy males received oral single doses of 12.5 mg (R)-carvedilol, 12.5 mg (S)-carvedilol and 25 mg (R,S)-carvedilol in a cross-over fashion; 11 patients with essential arterial hypertension were given 25 mg (R,S)-carvedilol. Exercise was performed 3 hours following drug intake, and blood samples were taken at rest, at the end of exercise, and after 15 min of recovery. Plasma concentrations of (R)- and (S)-carvedilol were determined by HPLC.
Plasma concentrations of (R)-carvedilol were 2- to 3-fold higher than those of (S)-carvedilol (p < 0.05 in all cases). Plasma concentrations of both (R)- and (S)-carvedilol remained unaffected during exercise and recovery.
Contrary to all other beta-blockers so far investigated, exercise had no effect on plasma concentrations of (R)- and (S)-carvedilol. We conclude that neither (R)- nor (S)-carvedilol is released from adrenergic cells during exercise, a feature that clearly distinguishes carvedilol from other beta-blockers. Thus, the human organism appears to handle (R)- and (S)-carvedilol differently than other beta-adrenoceptor antagonists. This finding deserves further investigation on a molecular and cellular level in order to clarify these differences between the pharmacokinetics of carvedilol and other beta-blockers.
体外研究表明,β受体阻滞剂可被肾上腺素能细胞摄取并释放。因此,运动期间β受体阻滞剂的血浆浓度会与肾上腺素和去甲肾上腺素的浓度一同升高。然而,运动对(R)-和(S)-卡维地洛血浆浓度的影响尚不清楚。
12名健康男性以交叉方式口服单剂量12.5mg(R)-卡维地洛、12.5mg(S)-卡维地洛和25mg(R,S)-卡维地洛;11名原发性高血压患者服用25mg(R,S)-卡维地洛。服药3小时后进行运动,在静息状态、运动结束时及恢复15分钟后采集血样。采用高效液相色谱法测定(R)-和(S)-卡维地洛的血浆浓度。
(R)-卡维地洛的血浆浓度比(S)-卡维地洛高2至3倍(所有情况均为p<0.05)。运动和恢复过程中,(R)-和(S)-卡维地洛的血浆浓度均未受影响。
与迄今研究的所有其他β受体阻滞剂相反,运动对(R)-和(S)-卡维地洛的血浆浓度没有影响。我们得出结论,运动期间肾上腺素能细胞不会释放(R)-或(S)-卡维地洛,这一特征使卡维地洛明显区别于其他β受体阻滞剂。因此,人体对(R)-和(S)-卡维地洛的处理方式似乎与其他β肾上腺素能受体拮抗剂不同。这一发现值得在分子和细胞水平上进一步研究,以阐明卡维地洛与其他β受体阻滞剂在药代动力学上的这些差异。